Amgen Inc. or Incyte Corporation: Who Leads in Yearly Revenue?

Amgen Inc. vs. Incyte Corporation: A Revenue Showdown

In the competitive landscape of biotechnology, Amgen Inc. and Incyte Corporation have been vying for dominance in annual revenue. Since 2014, Amgen has consistently outperformed Incyte, showcasing a robust growth trajectory. By 2023, Amgen's revenue surged by approximately 40% from its 2014 figures, reaching a peak of nearly $28 billion. In contrast, Incyte's revenue, while growing impressively by over 600% during the same period, remains a fraction of Amgen's, peaking at around $3.7 billion in 2023.

This revenue disparity highlights Amgen's established market presence and expansive product portfolio. Meanwhile, Incyte's rapid growth underscores its potential as an emerging player in the biotech sector. As both companies continue to innovate, the coming years will be crucial in determining whether Incyte can close the gap or if Amgen will maintain its lead.